Aeglea BioTherapeutics Total Assets 2015-2021 | AGLE

Aeglea BioTherapeutics total assets from 2015 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Aeglea BioTherapeutics Annual Total Assets
(Millions of US $)
2020 $162
2019 $83
2018 $78
2017 $56
2016 $67
2015 $39
2014 $3
Aeglea BioTherapeutics Quarterly Total Assets
(Millions of US $)
2021-09-30 $129
2021-06-30 $147
2021-03-31 $164
2020-12-31 $162
2020-09-30 $156
2020-06-30 $173
2020-03-31 $65
2019-12-31 $83
2019-09-30 $100
2019-06-30 $117
2019-03-31 $129
2018-12-31 $78
2018-09-30 $71
2018-06-30 $80
2018-03-31 $50
2017-12-31 $56
2017-09-30 $61
2017-06-30 $67
2017-03-31 $61
2016-12-31 $67
2016-09-30 $72
2016-06-30 $77
2016-03-31 $36
2015-12-31 $39
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.304B $0.004B
Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $122.991B 7.77
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.439B 21.07
Biohaven Pharmaceutical Holding (BHVN) United States $7.159B 0.00
Arcus Biosciences (RCUS) United States $3.161B 0.00
Emergent Biosolutions (EBS) United States $2.298B 8.26
ADC Therapeutics SA (ADCT) Switzerland $1.545B 0.00
Myovant Sciences (MYOV) United Kingdom $1.443B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.348B 0.00
SQZ Biotechnologies (SQZ) United States $0.329B 0.00
Enzo Biochem (ENZ) United States $0.163B 16.00